Speaker
Description
Background: Uncontrolled hyperphosphatemia is the main difficulty facing staff treating patients with end-stage renal disease on hemodialysis. Sevelamer and calcium-containing phosphate binder have been associated with cost burden and tissue calcification, respectively. Therefore, the current trial was targeted to investigate the efficacy and tolerability of a new phosphate binder, ferric citrate, in a sample of Iraqi patients with end-stage renal disease on hemodialysis.
Method: prospective, active-controlled, randomized study was carried out in Babylon governorate, at the dialysis center in Al-Imam Al-Sadiq hospital. Participants were allocated randomly into two groups, one using ferric citrate with a dose of 6 g/day and the other using calcium carbonate with a dose of 3 g/day for two months. Serum phosphate, serum calcium, and serum intact parathyroid hormone were analyzed as well as the primary cause, age, and gender were reported at the base line of the study. Furthermore, the tolerability variables, adherence and gastrointestinal side effects, were reported at the end of the trial.
Results: A total of 50 patients completed the trial. The ferric citrate group exhibited a decline in serum phosphate and intact parathyroid hormone more than the calcium carbonate group (p 0.05). There was similarity in gastrointestinal side effects reporting in both groups, with a higher adherence rate seen in the ferric citrate group.
Conclusion: the use of ferric citrate for two months was seen effectively control serum phosphate level and intact parathyroid hormone. In addition, the current phosphate binder, ferric citrate, was associated with more adherence than calcium carbonate with similar in gastrointestinal side effects. Ferric citrate may be suitable alternative as phosphate binder in Iraqi participants.
| Field/discipline | Clinical/Social Pharmacy |
|---|---|
| Has the manuscript been published? | Not published |
| Intend to be published in the conference journal (IJPS)? | Yes |
